Sudan virus

GeoVax Announces Publication of Lassa Fever Vaccine Study Results

Retrieved on: 
Wednesday, September 4, 2019
Infectious diseases, Medicine, Animal diseases, Tropical diseases, Biological weapons, Zoonoses, Viral hemorrhagic fever, Ebola virus disease, Marburg virus disease, Zaire ebolavirus, Sudan virus, Modified vaccinia Ankara

GeoVaxs Lassa fever vaccine (GEO-LM01) is based on the Companys novel Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform, which generates noninfectious VLPs in the individual being vaccinated.

Key Points: 
  • GeoVaxs Lassa fever vaccine (GEO-LM01) is based on the Companys novel Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform, which generates noninfectious VLPs in the individual being vaccinated.
  • Lassa fever surpasses Ebola, Marburg, and all other hemorrhagic fevers except Dengue in its public health impact.
  • GEO-LM01 is one component of a multivalent hemorrhagic fever virus vaccine being developed by GeoVax.
  • The other vaccine components are for protection against Sudan virus (SUDV), Marburg virus (MARV), and Ebola virus (EBOV).